Opinion|Videos|September 20, 2024
Evaluating Combination Strategies in R/R MM: TRIMM-2, TRIMM-3, MajesTEC-3
Focusing on clinical trials evaluating combination strategies with bispecifics, Larysa J. Sanchez, MD, discusses the TRIMM-2, TRIMM-3, and MajesTEC-3 studies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Please comment on the clinical trials evaluating combination strategies with bispecifics:
- Talquetamab
- TRIMM-2
- TRIMM-3
- Teclistamab
- MajesTEC-3
Advertisement
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
4
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
5